Scalper1 News
Embattled specialty drugmaker Allergan on Wednesday beat Wall Street’s first-quarter earnings estimates and raised its guidance, but the company’s stock slid 0.3% to close at 165.87 as its future remained in doubt. Allergan (AGN) reported earnings of $1.18 a share, up 20% from the year-earlier quarter and beating analysts’ consensus by 5 cents. Sales rose 13% to $1.62 billion, in line with estimates. Guidance followed a similar pattern. For the Scalper1 News
Scalper1 News